Insulin receptor substrates (IRS) serve as downstream messengers from activated cell surface receptors to numerous signaling pathway cascades. One of these pathways, phosphoinositide 3-kinase (PI3K), frequently displays aberrant function in the setting of cancer. IRS proteins are capable of both regulating and activating PI3K, depending on the cell of origin. As such, both prohost and protumor functions have been described for IRS proteins in human cancers. IRS proteins may eventually serve as biomarkers of PI3K activity, and serve a much-needed role as a guide to using targeted pathway therapy. Additionally, IRS-1 could be indirectly targeted in lung cancer, by inhibiting neutrophil elastase, which functions to degrade IRS-1 in lung tumor cells, thereby generating PI3K hyperactivity. Clin Cancer Res; 17(2); 206–11. ©2010 AACR. Clin Cancer Res; 17(2); 206–11. ©2010 AACR.

Insulin receptor substrates (IRS) are signaling adaptor proteins that function as intermediates of activated cell surface receptors, most notably for the insulin receptor (IR) and insulin-like growth factor receptor (IGF-IR; refs. 1–3). More recently, IRS proteins have been shown to signal downstream of integrin, cytokine, and steroid hormones receptors as well (4, 5), although these functions are poorly understood when compared with the “canonical” (IR- and IGF-IR–mediated) properties of IRS proteins. By mediating the activities of these receptors, IRS proteins interface with several signaling pathways, thereby impacting numerous aspects of cell behavior, including metabolism, motility, survival, and proliferation (Fig. 1). The majority of IRS protein research to date has centered upon the study of glucose metabolism and the pathogenesis of diabetes. Reports pertaining to the roles of IRS proteins in cancer progression are beginning to emerge (6).

Figure 1.

IRS-1 regulates downstream signaling of IR/IGF-IR. IRS-1 is a homeostatic regulator of PI3K signaling in lung tumor cells. IRS-1 has serine and tyrosine phosphorylation sites that bind SH2 domain–containing proteins including p85, Grb2, and SHIP2, among others. IRS-1 recruits PI3K and MEK/ERK via interaction with the regulatory p85 subunit and GRB2, respectively. The catalytic subunit of PI3K, p110, is now available to convert PIP2 to PIP3. PIP3 activates PDK-1, which subsequently phosphorylates AKT, enhancing cell survival, proliferation, and growth. Downstream effectors of AKT inhibit apoptosis via inhibition of Bad, Bim, Bax, and caspase 9, and activation of BCL-XL and Bcl-2. Tumor cell proliferation is promoted by the inhibition of GSK3, which targets cyclin D1 for proteasomal degradation. Increased protein synthesis results from activation of the mTOR pathway. The MEK/ERK pathway also promotes proliferation via interaction of IR/IGF-IR with IRS or Shc proteins. A feedback loop exists between the PI3K/AKT signaling pathway and IRS-1, in which IRS-1 is degraded through the ubiquitin-proteasome degradation pathway. The above pathways have been well established in metabolically active tissues including adipose and muscle. The above figure, however, describes an alternative to those established paradigms. In lung cancer cells, the PI3K/AKT pathway is weakly activated by IRS-1. IRS-1 acts homeostatically to prevent activation of PI3K by more potent mitogens, including PDGF. Therefore, the loss of IRS-1 increases the amount of available PI3K, which can then be activated by these mitogens causing much greater pathway activation. As shown, neutrophil elastase (NE) can enter tumor cells and degrade IRS-1 during tumor-associated neutrophilic inflammation allowing other RTKs to control PI3K signaling.

Figure 1.

IRS-1 regulates downstream signaling of IR/IGF-IR. IRS-1 is a homeostatic regulator of PI3K signaling in lung tumor cells. IRS-1 has serine and tyrosine phosphorylation sites that bind SH2 domain–containing proteins including p85, Grb2, and SHIP2, among others. IRS-1 recruits PI3K and MEK/ERK via interaction with the regulatory p85 subunit and GRB2, respectively. The catalytic subunit of PI3K, p110, is now available to convert PIP2 to PIP3. PIP3 activates PDK-1, which subsequently phosphorylates AKT, enhancing cell survival, proliferation, and growth. Downstream effectors of AKT inhibit apoptosis via inhibition of Bad, Bim, Bax, and caspase 9, and activation of BCL-XL and Bcl-2. Tumor cell proliferation is promoted by the inhibition of GSK3, which targets cyclin D1 for proteasomal degradation. Increased protein synthesis results from activation of the mTOR pathway. The MEK/ERK pathway also promotes proliferation via interaction of IR/IGF-IR with IRS or Shc proteins. A feedback loop exists between the PI3K/AKT signaling pathway and IRS-1, in which IRS-1 is degraded through the ubiquitin-proteasome degradation pathway. The above pathways have been well established in metabolically active tissues including adipose and muscle. The above figure, however, describes an alternative to those established paradigms. In lung cancer cells, the PI3K/AKT pathway is weakly activated by IRS-1. IRS-1 acts homeostatically to prevent activation of PI3K by more potent mitogens, including PDGF. Therefore, the loss of IRS-1 increases the amount of available PI3K, which can then be activated by these mitogens causing much greater pathway activation. As shown, neutrophil elastase (NE) can enter tumor cells and degrade IRS-1 during tumor-associated neutrophilic inflammation allowing other RTKs to control PI3K signaling.

Close modal

Six IRS proteins have been described; however, IRS-3 is expressed only in rodents (7), IRS-4 displays limited tissue expression (brain and thymus; ref. 8), and IRS-5 and IRS-6 are structurally dissimilar from the others (9). Therefore, most of the attention has been focused on IRS-1 and IRS-2, both of which are widely expressed. IRS proteins share similar structural domains including an N-terminal pleckstrin homology domain and a phospho-tyrosine binding (PTB) domain, which is required for binding NPEY motifs in the juxtamembrane region of ligand-activated IR and IGF-IR (10). The carboxy terminus contains numerous serine and tyrosine phosphorylation sites that bind PTB containing src-homology-2 (SH2) proteins, including p85, Grb2, Nck, the phosphotyrosine phosphatase SHP2, Fyn, and others (11). Although IRS proteins are not catalytically active, they are capable of impacting numerous signaling cascades via interaction with SH2 proteins.

Despite sharing binding partners and structural similarities, IRS-1 and IRS-2 functions are not entirely overlapping. IRS-1−/− mice display low birth weight and glucose intolerance, but do not develop overt diabetes (12). The generation of these mice led to the discovery of IRS-2, which was believed to compensate for the loss of IRS-1 and prevent additional metabolic derangements. IRS-2−/− mice have subsequently been shown to develop diabetes as a consequence of decreased β-cell function and insulin resistance (13). Therefore, IRS-1 and IRS-2 possess both overlapping and unique properties, although their relative contribution to cancer growth and invasiveness has yet to be elucidated.

Though IRS proteins signal through many pathways, their predominant function seems to be activation and/or regulation of the phosphoinositide 3-kinase (PI3K) and extracellular signal regulated kinase (ERK) pathways. PI3K is a heterodimer with separate regulatory (p85) and catalytic subunits (p110). In its resting state, PI3K exists as an inactive p85-p110 complex. Upon the activation of a receptor tyrosine kinase (RTK), meaning phosphorylation of its cytoplasmic tail, the p85-p110 complex is recruited to the receptor by interaction of an SH2 domain on p85 with phosphotyrosine residues on the RTK (14). This interaction is believed to release the inhibitory effects of p85 on the catalytic p110 (15). p110 is now able to interact with its lipid substrates, the phosphatidylinositols, and convert PIP2 to PIP3. Recruitment of PI3K by RTK also puts p110 in close proximity to these lipid substrates residing in the plasma membrane. The major exception to this schema is that PI3K can be activated by signal adapter proteins, such as IRS-1 and IRS-2, rather than by RTKs themselves (5). Of note, IRS-mediated activation of PI3K requires that phosphorylated YMXM motifs occupy both SH2 domains within p85 (16).

Generation of PIP3 by activated PI3K near the plasma membrane results in interaction with, and subsequent phosphorylation of, its primary substrate, Akt (17). Once activated, pAkt uses extensive downstream signaling pathways to enhance tumor viability in one of three ways: cell survival, cell proliferation (number), and cell growth (size; ref. 18). The avoidance of apoptosis, achieved by the direct phosphorylation of BAD by pAkt, is generally considered the predominant function of PI3K/Akt in cancer cells (19). However, PI3K/Akt also promotes tumor cell proliferation by causing an accumulation of cyclin D1, which regulates G1/S phase transition (20). This is accomplished by inhibition of p27, p21, and glycogen synthase kinase-3β (GSK3β), which target cyclin D1 for proteasomal degradation, when active (21, 22).

PI3K activity seems to be regulated in two ways. The first is simply the activation of the p85 subunit, which maintains p110 in an inactive state at baseline. The second is the constitutively active negative repressor, phosphatase and tensin homolog (PTEN). PTEN regulates the output of PI3K by dephosphorylating PIP3 back to PIP2 (23). Mutation in PTEN is relatively common in cancers, and has been linked to PI3K hyperactivity in several, including prostate carcinoma, hepatocellular carcinoma (HCC), melanoma, renal-cell carcinoma, and glioblastoma, among others (24–28). Interestingly, PTEN mutation is rare in some cancers, including lung cancer (29). The common explanations for PI3K hyperactivity in the setting of preserved PTEN expression has been activation of PI3K by K-ras and genetic mutations within the PI3K pathway (e.g., PIK3CA), both of which possess the ability to by-pass regulatory machinery (30–32).

Although generally considered positive effectors of growth factor, IRS proteins may, in fact, function as homeostatic regulators of PI3K output in certain tissues. Supporting evidence of this theory includes the fact that IRS-p85 interaction takes place within the cytosol, pulling PI3K away from its lipid substrates and creating compartmentalization phenomena for signaling (33). Furthermore, IRS proteins display low potency for ligand interaction. As an example, IRS-1-Grb2 binding results in nearly 10-fold less pathway output when compared with other common Grb2-binding partners (34).

IRS proteins in cancer

Preclinical studies have shown both protumor and prohost functions for IRS proteins in cancer. IRS-1 overexpression has been shown to induce malignant transformation in both embryonic mouse fibroblasts (35) and NIH3T3 fibroblasts (36, 37). Such cells are capable of tumor formation in nude mice, a process displaying MEK/ERK hyperactivity and requiring IGF-IR, as embryonic fibroblasts derived from IGF-IR−/− mice are resistant to IRS-1–induced transformation (38). Oncogenic transformation by IRS-1 has not been described for other cell types.

Both IRS-1 and IRS-2 are commonly overexpressed in HCC, which is characterized by IR and IGF-IR signaling hyperactivity (39, 40). IRS-1 overexpression in HCC cell lines prevents TGF-β–induced apoptosis (41). In fact, transfection of these cells with a dominant-negative IRS-1 reverses their malignant phenotype (42).

The role of IRS-1 in breast cancer has been difficult to elucidate, as both prohost and protumor functions have been described. Simple overexpression of IRS-1 in MCF-7 breast cancer cells accelerates their growth, whereas IRS-1 gene silencing ultimately results in apoptosis, at least under serum-free conditions (43, 44). IRS-1 and IRS-2 transgenic mice both display enhanced tumor growth, metastasis, and resistance from apoptosis (45). These mice develop mammary gland hyperplasia early in life, and display unusual tumor histology, and not the typically encountered adenocarcinoma (46). Thus, these overexpression studies may not be representative of pathophysiologic properties of IRS proteins in human cancers. As such, IRS-1–silenced tumor xenografts actually displayed increased metastasis (47), consistent with a prohost role for IRS-1. Additionally, studies of IRS-1 in human breast cancer show that IRS-1 expression is lost in clinically advanced cases (48).

We have recently described a prohost role for IRS-1 in lung cancer (49). While investigating the role of neutrophil elastase in lung cancer, we observed that neutrophil elastase–deficient tumors in the Lox-Stop-Lox-K-ras (LSL-K-ras) model of lung adenocarcinoma (50) accumulated intracellular IRS-1 protein, whereas neutrophil elastase–sufficient tumors contained scant IRS-1. We were able to show that IRS-1 is an intracellular proteolytic target for neutrophil elastase, which induced cellular proliferation and pAkt production upon the degradation of IRS-1. Ultimately, we discovered that the loss of IRS-1 functioned to increase the pool of bio-available PI3K, rendering p85 free to interact with the more potent growth factors present in lung cancer cells, especially the platelet-derived growth factor (PDGF) and receptor (PDGFR) complex (51). Consistent with this concept, IRS-1 gene silencing in lung cancer cells resulted in cellular proliferation and pAkt production, whereas IRS-1 overexpression induced cell cycle arrest. Furthermore, a correlation of the presence of neutrophil elastase with the absence of IRS-1 was established in human lung adenocarcinomas. Thus, IRS-1 is capable of both growth promoting and growth regulatory functions in cancers, depending on the cell of origin.

With respect to IRS proteins, studies translating the findings observed in murine models to human cancers are sparse. However, the existing studies do support the hypothesis that IRS-1 can function both for and against the host, depending on the cell of origin. Nearly all studies suggesting that IRS proteins function as positive effector of growth factor were done in metabolically active tissues, such as myocytes, adipocytes, and hepatocytes (3). As such, IRS-1 seems to promote tumor growth in malignancies that arise from such cell types including leiomyosarcomas, myosarcomas, liposarcomas, rhabdomyosarcomas, and HCCs (52). Interestingly, the single study of IRS-1 in non–small cell lung cancer (NSCLC) showed that the loss of IRS-1 expression correlated with increased tumor growth (53), consistent with our findings with respect to IRS-1 in murine models of lung adenocarcinoma. Further evidence that IRS-1 homeostatically regulates PI3K in cancer can be elucidated from the study of G972R polymorphism. The presence of the G972R polymorphism within IRS-1 decreases interaction with p85 (54), such that PI3K will be activated by other growth factors within the cell. This polymorphism has been associated with an increased risk of prostate cancer (55).

Two potential clinical applications can be found in IRS proteins in human cancers: (1) use as a biomarker for PI3K ± MEK/ERK activity and therapeutic response to inhibitors of these respective pathways, and (2) indirectly maintaining IRS-1 levels within tumor cells by inhibiting neutrophil elastase, which proteolytically degrades IRS-1 within lung cancer cells.

Inhibition of PI3K, of which IRS-1 is an integral component, is currently under investigation in numerous early phase trials (56, 57). It is generally accepted that the successful application of PI3K inhibitors (and all pathway-directed therapies for that matter) will require biomarkers predictive of tumor response to a given therapy. Early studies employing targeted pathway inhibition in human cancers have already highlighted this point. Specifically, the presence of K-ras mutation in colorectal cancer has been used to predict response to anti–epidermal growth factor receptor (EGFR) therapy (58), and Her2 overexpression has been used to predict response to trastuzumab (herceptin; ref. 59).

No biomarkers have been validated for response to PI3K inhibition. Some markers are predictive of prognosis, such as combined analysis of PTEN and PIK3CA status, and may yet prove useful in predicting response to PI3K antagonism (60–62). The first step toward using IRS-1 and/or IRS-2 in this capacity will be to acquire the necessary translational studies to clearly define the impact of the presence or absence of IRS-1/IRS-2 on PI3K activity level, and to correlate these findings with meaningful clinical outcomes data for each distinct cancer subtype. As described above, it is likely that IRS-1-PI3K interaction will produce differential effects on cell behavior depending on the cell of origin. Therefore, it is plausible that IRS-1 levels will predict opposing outcomes when comparing HCC to NSCLC, for example. We propose that the loss of IRS-1 in lung cancers will result in paradoxical hyperactivity of PI3K, independent of genetic mutations that commonly cause PI3K hyperactivity (K-ras, PIK3CA, PTEN, etc.). PI3K hyperactive tumors (pAkt positive) that are devoid of IRS-1 may represent a subclass amenable to inhibition of PI3K, and possibly to MEK/ERK antagonism. Commonly employed expression profiles will continually fail to identify changes in IRS-1 expression, as IRS-1 is posttranslationally degraded by components within the tumor microenvironment (neutrophil elastase). Therefore, detailed analyses of IRS-1 protein content (immunohistochemistry, immunoblot) and gene expression (quantitative PCR) must be entertained to identify the nature of IRS-1 loss in each cancer type, and its impact on PI3K activity and clinical outcomes.

The most logical way to manipulate tumor IRS-1 content for therapeutic benefit would be to use an indirect approach. IRS-1 loss in human lung adenocarcinoma seems to be a result of neutrophil elastase–mediated degradation. Therefore, antagonism of neutrophil elastase within the tumor microenvironment should preserve IRS-1 content within tumor cells and maintain homeostatic regulation of PI3K, at least in lung tumors. We employed this approach to successfully reduce lung tumor burden in LSL-K-ras tumor–bearing mice using the neutrophil elastase inhibitor ONO-5046. Neutrophil elastase inhibitors were previously developed as a potential treatment for chronic obstructive pulmonary disease (COPD) and emphysema; however, these agents were never fully tested given the difficult nature to carry out clinical trials in COPD (large cohort size, lack of adequate phenotypic markers to determine response, etc.) and the likelihood that other elastin-degrading enzymes (i.e., matrix metalloproteinases) would drive disease progression independent of neutrophil elastase (63–65). Despite these difficulties, some neutrophil elastase inhibitors are currently undergoing early phase investigation in human COPD (66), and if they prove safe, could readily be tested in human lung adenocarcinoma. Plans to do such studies are underway within our group.

IRS proteins interface with essential signaling pathways commonly implicated in tumor development and progression. Current data suggest that IRS proteins may function either for or against the host in the setting of cancer, depending upon the cell of origin. Further translational studies will be required to determine the impact of IRS-1 and IRS-2 expression or loss on outcomes in various human malignancies. These data may prove useful for the development of IRS protein levels as biomarkers of response to emerging targeted pathway-inhibiting therapies. Preservation of IRS-1 levels within lung tumor cells by inhibiting the IRS-1 degrading enzyme neutrophil elastase may prove an effective therapeutic strategy for patients with NSCLC.

No potential conflicts of interest were disclosed.

1.
Sun
XJ
,
Rothenberg
P
,
Kahn
CR
,
Backer
JM
,
Araki
E
,
Wilden
PA
, et al
Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein
.
Nature
1991
;
352
:
73
7
.
2.
Sun
XJ
,
Wang
LM
,
Zhang
Y
,
Yenush
L
,
Myers
MG
 Jr
,
Glasheen
E
, et al
Role of IRS-2 in insulin and cytokine signalling
.
Nature
1995
;
377
:
173
7
.
3.
White
MF
. 
IRS proteins and the common path to diabetes
.
Am J Physiol Endocrinol Metab
2002
;
283
:
E413
22
.
4.
Yamauchi
T
,
Kaburagi
Y
,
Ueki
K
,
Tsuji
Y
,
Stark
GR
,
Kerr
IM
, et al
Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3-kinase activation via JAK2 kinase
.
J Biol Chem
1998
;
273
:
15719
26
.
5.
White
MF
,
Yenush
L
. 
The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action
.
Curr Top Microbiol Immunol
1998
;
228
:
179
208
.
6.
Dearth
RK
,
Cui
X
,
Kim
HJ
,
Hadsell
DL
,
Lee
AV
. 
Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2
.
Cell Cycle
2007
;
6
:
705
13
.
7.
Smith-Hall
J
,
Pons
S
,
Patti
ME
,
Burks
DJ
,
Yenush
L
,
Sun
XJ
, et al
The 60 kDa insulin receptor substrate functions like an IRS protein (pp60IRS3) in adipose cells
.
Biochemistry
1997
;
36
:
8304
10
.
8.
Fantin
VR
,
Sparling
JD
,
Slot
JW
,
Keller
SR
,
Lienhard
GE
,
Lavan
BE
. 
Characterization of insulin receptor substrate 4 in human embryonic kidney 293 cells
.
J Biol Chem
1998
;
273
:
10726
32
.
9.
Cai
D
,
Dhe-Paganon
S
,
Melendez
PA
,
Lee
J
,
Shoelson
SE
. 
Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5
.
J Biol Chem
2003
;
278
:
25323
30
.
10.
Yenush
L
,
Zanella
C
,
Uchida
T
,
Bernal
D
,
White
MF
. 
The pleckstrin homology and phosphotyrosine binding domains of insulin receptor substrate 1 mediate inhibition of apoptosis by insulin
.
Mol Cell Biol
1998
;
18
:
6784
94
.
11.
Taniguchi
CM
,
Emanuelli
B
,
Kahn
CR
. 
Critical nodes in signalling pathways: insights into insulin action
.
Nat Rev Mol Cell Biol
2006
;
7
:
85
96
.
12.
Araki
E
,
Lipes
MA
,
Patti
ME
,
Brüning
JC
,
Haag
B
 3rd
,
Johnson
RS
, et al
Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene
.
Nature
1994
;
372
:
186
90
.
13.
Withers
DJ
,
Gutierrez
JS
,
Towery
H
,
Burks
DJ
,
Ren
JM
,
Previs
S
, et al
Disruption of IRS-2 causes type 2 diabetes in mice
.
Nature
1998
;
391
:
900
4
.
14.
Fruman
DA
,
Meyers
RE
,
Cantley
LC
. 
Phosphoinositide kinases
.
Annu Rev Biochem
1998
;
67
:
481
507
.
15.
Yu
J
,
Zhang
Y
,
McIlroy
J
,
Rordorf-Nikolic
T
,
Orr
GA
,
Backer
JM
. 
Regulation of the p85/p110 phosphatidylinositol 3¢-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit
.
Mol Cell Biol
1998
;
18
:
1379
87
.
16.
Backer
JM
,
Myers
MG
 Jr
,
Shoelson
SE
, et al
Phosphatidylinositol 3′-kinase is activated by association with IRS-1 during insulin stimulation
.
EMBO J
1992
;
11
:
3469
79
.
17.
Datta
SR
,
Brunet
A
,
Greenberg
ME
. 
Cellular survival: a play in three Akts
.
Genes Dev
1999
;
13
:
2905
27
.
18.
Fresno
Vara JA
,
Casado
E
,
de Castro
J
,
Cejas
P
,
Belda-Iniesta
C
,
Gonzalez-Baron
M
. 
PI3K/Akt signalling pathway and cancer
.
Cancer Treat Rev
2004
;
30
:
193
204
.
19.
Datta
SR
,
Dudek
H
,
Tao
X
,
Masters
S
,
Fu
H
,
Gotoh
Y
, et al
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
.
Cell
1997
;
91
:
231
41
.
20.
Baldin
V
,
Lukas
J
,
Marcote
MJ
,
Pagano
M
,
Draetta
G
. 
Cyclin D1 is a nuclear protein required for cell cycle progression in G1
.
Genes Dev
1993
;
7
:
812
21
.
21.
Diehl
JA
,
Cheng
M
,
Roussel
MF
,
Sherr
CJ
. 
Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization
.
Genes Dev
1998
;
12
:
3499
511
.
22.
Graff
JR
,
Konicek
BW
,
McNulty
AM
,
Wang
Z
,
Houck
K
,
Allen
S
, et al
Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression
.
J Biol Chem
2000
;
275
:
24500
5
.
23.
Stambolic
V
,
Suzuki
A
,
de la Pompa
JL
,
Brothers
GM
,
Mirtsos
C
,
Sasaki
T
, et al
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
.
Cell
1998
;
95
:
29
39
.
24.
Li
J
,
Yen
C
,
Liaw
D
,
Bose
S
,
Wang
SI
,
Puc
J
, et al
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
.
Science
1997
;
275
:
1943
7
.
25.
Hu
TH
,
Huang
CC
,
Lin
PR
,
Chang
HW
,
Ger
LP
,
Lin
YW
, et al
Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma
.
Cancer
2003
;
97
:
1929
40
.
26.
Alimov
A
,
Li
C
,
Gizatullin
R
,
Fredriksson
V
,
Sundelin
B
,
Klein
G
, et al
Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma
.
Anticancer Res
1999
;
19
:
3841
6
.
27.
Wang
SI
,
Puc
J
,
Li
J
,
Bruce
JN
,
Cairns
P
,
Sidransky
D
, et al
Somatic mutations of PTEN in glioblastoma multiforme
.
Cancer Res
1997
;
57
:
4183
6
.
28.
Celebi
JT
,
Shendrik
I
,
Silvers
DN
,
Peacocke
M
. 
Identification of PTEN mutations in metastatic melanoma specimens
.
J Med Genet
2000
;
37
:
653
7
.
29.
Forgacs
E
,
Biesterveld
EJ
,
Sekido
Y
,
Fong
K
,
Muneer
S
,
Wistuba
II
, et al
Mutation analysis of the PTEN/MMAC1 gene in lung cancer
.
Oncogene
1998
;
17
:
1557
65
.
30.
Cully
M
,
You
H
,
Levine
AJ
,
Mak
TW
. 
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
.
Nat Rev Cancer
2006
;
6
:
184
92
.
31.
Rodriguez-Viciana
P
,
Warne
PH
,
Dhand
R
,
Vanhaesebroeck
B
,
Gout
I
,
Fry
MJ
, et al
Phosphatidylinositol-3-OH kinase as a direct target of Ras
.
Nature
1994
;
370
:
527
32
.
32.
Engelman
JA
,
Chen
L
,
Tan
X
,
Crosby
K
,
Guimaraes
AR
,
Upadhyay
R
, et al
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
.
Nat Med
2008
;
14
:
1351
6
.
33.
Nave
BT
,
Haigh
RJ
,
Hayward
AC
,
Siddle
K
,
Shepherd
PR
. 
Compartment-specific regulation of phosphoinositide 3-kinase by platelet-derived growth factor and insulin in 3T3-L1 adipocytes
.
Biochem J
1996
;
318
:
55
60
.
34.
Ceresa
BP
,
Pessin
JE
. 
Insulin regulation of the Ras activation/inactivation cycle
.
Mol Cell Biochem
1998
;
182
:
23
9
.
35.
D'Ambrosio
C
,
Keller
SR
,
Morrione
A
,
Lienhard
GE
,
Baserga
R
,
Surmacz
E
. 
Transforming potential of the insulin receptor substrate 1
.
Cell Growth Differ
1995
;
6
:
557
62
.
36.
Tanaka
S
,
Ito
T
,
Wands
JR
. 
Neoplastic transformation induced by insulin receptor substrate-1 overexpression requires an interaction with both Grb2 and Syp signaling molecules
.
J Biol Chem
1996
;
271
:
14610
6
.
37.
Ito
T
,
Sasaki
Y
,
Wands
JR
. 
Overexpression of human insulin receptor substrate 1 induces cellular transformation with activation of mitogen-activated protein kinases
.
Mol Cell Biol
1996
;
16
:
943
51
.
38.
DeAngelis
T
,
Chen
J
,
Wu
A
,
Prisco
M
,
Baserga
R
. 
Transformation by the simian virus 40 T antigen is regulated by IGF-I receptor and IRS-1 signaling
.
Oncogene
2006
;
25
:
32
42
.
39.
Boissan
M
,
Beurel
E
,
Wendum
D
,
Rey
C
,
Lécluse
Y
,
Housset
C
, et al
Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma
.
Am J Pathol
2005
;
167
:
869
77
.
40.
Nehrbass
D
,
Klimek
F
,
Bannasch
P
. 
Overexpression of insulin receptor substrate-1 emerges early in hepatocarcinogenesis and elicits preneoplastic hepatic glycogenosis
.
Am J Pathol
1998
;
152
:
341
5
.
41.
Tanaka
S
,
Wands
JR
. 
Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis
.
Cancer Res
1996
;
56
:
3391
4
.
42.
Tanaka
S
,
Wands
JR
. 
A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype
.
J Clin Invest
1996
;
98
:
2100
8
.
43.
Nolan
MK
,
Jankowska
L
,
Prisco
M
,
Xu
S
,
Guvakova
MA
,
Surmacz
E
. 
Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells
.
Int J Cancer
1997
;
72
:
828
34
.
44.
Surmacz
E
,
Burgaud
JL
. 
Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation
.
Clin Cancer Res
1995
;
1
:
1429
36
.
45.
Dearth
RK
,
Cui
X
,
Kim
HJ
,
Kuiatse
I
,
Lawrence
NA
,
Zhang
X
, et al
Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2
.
Mol Cell Biol
2006
;
26
:
9302
14
.
46.
Rosner
A
,
Miyoshi
K
,
Landesman-Bollag
E
,
Xu
X
,
Seldin
DC
,
Moser
AR
, et al
Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors
.
Am J Pathol
2002
;
161
:
1087
97
.
47.
Ma
Z
,
Gibson
SL
,
Byrne
MA
,
Zhang
J
,
White
MF
,
Shaw
LM
. 
Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis
.
Mol Cell Biol
2006
;
26
:
9338
51
.
48.
Rocha
RL
,
Hilsenbeck
SG
,
Jackson
JG
,
VanDenBerg
CL
,
Weng
C
,
Lee
AV
, et al
Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival
.
Clin Cancer Res
1997
;
3
:
103
9
.
49.
Houghton
AM
,
Rzymkiewicz
DM
,
Ji
H
,
Gregory
AD
,
Egea
EE
,
Metz
HE
, et al
Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth
.
Nat Med
2010
;
16
:
219
23
.
50.
Jackson
EL
,
Willis
N
,
Mercer
K
,
Bronson
RT
,
Crowley
D
,
Montoya
R
, et al
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
.
Genes Dev
2001
;
15
:
3243
8
.
51.
Antoniades
HN
,
Galanopoulos
T
,
Neville-Golden
J
,
O'Hara
CJ
. 
Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products
.
Proc Natl Acad Sci USA
1992
;
89
:
3942
6
.
52.
Chang
Q
,
Li
Y
,
White
MF
,
Fletcher
JA
,
Xiao
S
. 
Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications
.
Cancer Res
2002
;
62
:
6035
8
.
53.
Han
CH
,
Cho
JY
,
Moon
JT
,
Kim
HJ
,
Kim
SK
,
Shin
DH
, et al
Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer
.
Oncol Rep
2006
;
16
:
1205
10
.
54.
Sentinelli
F
,
Filippi
E
,
Cavallo
MG
,
Romeo
S
,
Fanelli
M
,
Baroni
MG
. 
The G972R variant of the insulin receptor substrate-1 gene impairs insulin signaling and cell differentiation in 3T3L1 adipocytes; treatment with a PPARgamma agonist restores normal cell signaling and differentiation
.
J Endocrinol
2006
;
188
:
271
85
.
55.
Neuhausen
SL
,
Slattery
ML
,
Garner
CP
,
Ding
YC
,
Hoffman
M
,
Brothman
AR
. 
Prostate cancer risk and IRS1, IRS2, IGF1, and INS polymorphisms: strong association of IRS1 G972R variant and cancer risk
.
Prostate
2005
;
64
:
168
74
.
56.
Courtney
KD
,
Corcoran
RB
,
Engelman
JA
. 
The PI3K pathway as drug target in human cancer
.
J Clin Oncol
2010
;
28
:
1075
83
.
57.
Markman
B
,
Atzori
F
,
Perez-Garcia
J
,
Tabernero
J
,
Baselga
J
. 
Status of PI3K inhibition and biomarker development in cancer therapeutics
.
Ann Oncol
2010
;
21
:
683
91
.
58.
Allegra
CJ
,
Jessup
JM
,
Somerfield
MR
,
Hamilton
SR
,
Hammond
EH
,
Hayes
DF
, et al
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
.
J Clin Oncol
2009
;
27
:
2091
6
.
59.
Slamon
DJ
,
Leyland-Jones
B
,
Shak
S
,
Fuchs
H
,
Paton
V
,
Bajamonde
A
, et al
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
.
N Engl J Med
2001
;
344
:
783
92
.
60.
Sartore-Bianchi
A
,
Martini
M
,
Molinari
F
,
Veronese
S
,
Nichelatti
M
,
Artale
S
, et al
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
.
Cancer Res
2009
;
69
:
1851
7
.
61.
Berns
K
,
Horlings
HM
,
Hennessy
BT
,
Madiredjo
M
,
Hijmans
EM
,
Beelen
K
, et al
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
.
Cancer Cell
2007
;
12
:
395
402
.
62.
Perrone
F
,
Lampis
A
,
Orsenigo
M
,
Di Bartolomeo
M
,
Gevorgyan
A
,
Losa
M
, et al
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
.
Ann Oncol
2009
;
20
:
84
90
.
63.
Shapiro
SD
. 
COPD unwound
.
N Engl J Med
2005
;
352
:
2016
9
.
64.
Hautamaki
RD
,
Kobayashi
DK
,
Senior
RM
,
Shapiro
SD
. 
Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice
.
Science
1997
;
277
:
2002
4
.
65.
Houghton
AM
,
Quintero
PA
,
Perkins
DL
,
Kobayashi
DK
,
Kelley
DG
,
Marconcini
LA
, et al
Elastin fragments drive disease progression in a murine model of emphysema
.
J Clin Invest
2006
;
116
:
753
9
.
66.
Fitzgerald
MF
,
Fox
JC
. 
Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development
.
Drug Discov Today
2007
;
12
:
479
86
.